We claim:
1. A compound of formula (I)
or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof; wherein,
X represents N or C;
Rx and Ry combine together with the atoms to which they are attached to form a fused 5-membered heteroaryl substituted with 1 or 2 occurrence(s) of R6;
Rt and Rz independently represents hydrogen or alkyl;
R1 is hydrogen, halogen, cyano, hydroxy, amino, alkoxy, alkyl or haloalkyl;
R2 is hydrogen, halogen, alkyl or haloalkyl;
R3 is aryl, cycloalkyl, heterocyclyl or a group represented by a formula -CHRaRb, wherein the aryl, cycloalkyl and heterocyclyl are optionally substituted with 1, 2 or 3 substituent(s) independently selected from halogen, hydroxy, haloalkyl and alkyl;
Ra and Rb independently represent hydrogen, alkyl, alkoxy, alkoxy-alkyl, haloalkyl or cycloalkyl;
R4 at each occurrence is independently hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy or cycloalkyl; or any two adjacent R4 groups combine together with the atoms to which they are attached to form a fused 5-membered heteroaryl substituted with 1 or 2 occurrence(s) of R5;
R5 at each occurrence is independently hydrogen, alkyl, halogen, haloalkyl, cyano, alkoxy, haloalkoxy, amino, aryl, cycloalkyl, heterocycloalkyl or heteroaryl;
R6 at each occurrence is independently hydrogen, halogen, hydroxy, cyano, alkoxy, alkyl or cycloalkyl, wherein the alkyl is optionally substituted with 1 to 3 substituent(s) independently selected from hydroxy, oxo, halogen, alkylamino, alkoxy and heterocycloalkyl; and
n is 1, 2 or 3.
2. The compound of any one of claim 1 , wherein Rx and Ry combine together with the atoms to which they are attached to form a fused 5-membered heteroaryl substituted with 1 or 2 occurrence(s) of R6.
3. The compound of claim 2, wherein the fused 5-membered heteroaryl is selected from
To) Ton ob> [O>
>n-n \n